1-4 of 4
antiplatelet agents
Close
Sort by
Journal Articles

Systemic bevacizumab for refractory bleeding and transfusion-dependent anemia in Heyde syndrome

Clinical Trials & Observations
Andrew B. Song, Rahul Sakhuja, Nancy M. Gracin, Ronald Weinger, Raj S. Kasthuri, Hanny Al-Samkari
Journal: Blood Advances
Blood Adv (2021) 5 (19): 3850–3854.
https://doi.org/10.1182/bloodadvances.2021004810
Published: 2021
Journal Articles

ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease

Nathan T. Connell, Veronica H. Flood, Romina Brignardello-Petersen, Rezan Abdul-Kadir, Alice Arapshian, Susie Couper, Jean M. Grow, Peter Kouides, Michael Laffan, Michelle Lavin, Frank W. G. Leebeek, Sarah H. O’Brien, Margareth C. Ozelo, Alberto Tosetto, Angela C. Weyand, Paula D. James, Mohamad A. Kalot, Nedaa Husainat, Reem A. Mustafa
Journal: Blood Advances
Blood Adv (2021) 5 (1): 301–325.
https://doi.org/10.1182/bloodadvances.2020003264
Published: 2021
Includes: Supplemental data
Journal Articles

Antiplatelet therapy in the management of atherothrombosis: recent clinical advances

Clinical Trials & Observations
Noel C. Chan, Jeffrey I. Weitz
Journal: Blood Advances
Blood Adv (2018) 2 (14): 1806.
https://doi.org/10.1182/bloodadvances.2018005074
Published: 2018
Includes: Supplemental data
Journal Articles

Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy

Clinical Trials & Observations
William G. Jackson, Clara Oromendia, Ozan Unlu, Doruk Erkan, Maria T. DeSancho
Journal: Blood Advances
Blood Adv (2017) 1 (25): 2320–2324.
https://doi.org/10.1182/bloodadvances.2017008185
Published: 2017